Injectable Product Defects

Troubleshooting Injectable Product Defects: Particulate Matter, Fill Volume Deviations, and Turbidity Issues

Injectable product defects refer to any physical, chemical, or microbial issues that render the parenteral product non-compliant with pharmacopeial or regulatory specifications. These defects are detected during in-process checks, visual…

Injectable Defects Like Visible Particles? Sterile Process Fixes and Controls

Identifying defects in injectable products often begins with recognizing signals on the manufacturing floor or in quality control labs. Common symptoms of visible particle contamination may include the following:Click to…

pH drift detected during stability testing – FDA/MHRA inspection outcome

The first step in addressing a pH drift issue is to recognize and document the symptoms observed during stability testing. Symptoms may vary, but common signals include:Click to read the…

Visual inspection rejects during stability testing – FDA/MHRA inspection outcome

Identifying the early signs of visual inspection rejects is crucial for timely intervention. Common symptoms may include:Click to read the full article.

Endotoxin OOS during PAI readiness – FDA/MHRA inspection outcome

OOS results for endotoxin levels often signal deeper issues within the production environment. Key symptoms and signals that may precede or accompany these results include:Click to read the full article.

Visual inspection rejects post-sterile filtration – patient safety risk analysis

In the context of visual inspection for injectable products, symptoms signaling a potential issue can be broadly categorized into physical characteristics and inspection outcomes. Observations may include:Click to read the…

Fill volume variability during stability testing – patient safety risk analysis

Identifying symptoms of fill volume variability is crucial for early intervention. Key signals include:Click to read the full article.

Particulate matter detected after line intervention – patient safety risk analysis

The initial identification of particulate matter can occur through visual inspection, laboratory analysis, or even during visual container inspections. Symptoms may include:Click to read the full article.

Endotoxin OOS after line intervention – CAPA effectiveness failure

The first step in managing an endotoxin OOS incident is to recognize the symptoms. Symptoms may occur during routine testing, batch release, or even from internal audits. Signs of a…

Particulate matter detected during stability testing – patient safety risk analysis

The early identification of symptoms related to the presence of particulate matter is crucial for timely intervention. Common signals observed during stability testing include:Click to read the full article.

Visual inspection rejects during PAI readiness – FDA/MHRA inspection outcome

Visual inspection rejects often come with identifiable symptoms that provide early warnings of deeper issues. Common causes for rejection include:Click to read the full article.

Media fill failure during PAI readiness – CAPA effectiveness failure

Recognizing symptoms of media fill failure is the first step in directing a focused investigation. Instances may manifest as:Click to read the full article.